



# ASX Announcement

For immediate release

22 June 2009

## **Accounting treatment – conversion of USD\$1.5 billion funds on deposit to Australian dollars**

Melbourne, Australia (22 June 2009) – On 9 June 2009, CSL Limited (ASX:CSL) made an announcement to the Australian Securities Exchange regarding the termination of the Talecris Biotherapeutics merger agreement. During the subsequent media and market briefing (audio copy available on the company website at [www.csl.com.au](http://www.csl.com.au)) the company referred to an approximate AUD\$150 million foreign exchange benefit arising from selling forward into Australian dollars approximately USD\$1.5 billion held on deposit in anticipation of acquiring Talecris Biotherapeutics. At the time, the company indicated this amount was a cash benefit only.

Following audit advice, this foreign exchange benefit will now be reflected in the Group's Income Statement (Profit & Loss statement) for the period ending 30 June 2009. This transaction will result in a non recurring net profit after tax benefit of approximately AUD\$150 million.

After taking into consideration the previously disclosed transaction break fee and other termination costs the net financial impact is a non-recurring net profit after tax of approximately AUD\$80 million.

### **Investor Contact:**

Mark Dehring  
Head of Investor Relations  
Telephone: +61 (3) 9389 2818  
Email: [mark.dehring@csl.com.au](mailto:mark.dehring@csl.com.au)